Pharmidex attending the Global Business Accelerator visit to Switzerland
March 10, 2018

Pharmidex will be attending the Global Business Accelerator Program which is run by the Enterprise Europe Network and supported by Innovate UK.

The Enterprise Europe Network, supported by Innovate UK, are visiting Switzerland to focus on the pharmaceutical technology industry. The chosen companies will have the opportunity to meet pharmaceutical companies and key stakeholders based in Basel and attend ProcureCon Pharma in Zürich for the next three days


The Swiss pharmaceutical sector is a major employer with more than 40,000 people working directly for the industry. If the indirect work created through ancillary industries is included, as many as 172,000 jobs are related to the pharmaceutical industry. In addition, it accounts for up to a third of all Swiss exports, and the productivity of the industry is four times as high as that of the economy as a whole.


Three big clusters – the Lake Geneva area, the Basel region and Zürich-Zug-Lucerne – account for the lion’s share of the gross value added of the Swiss pharmaceutical industry and present many collabartive opputunities for UK companies. 


During the trip Pharmidex will also be attending ProcureCon Pharma, organised by Worldwide Business Research, will take place from 13 to 15 March 2018 in Zürich. Delegates will have the opportunity to join 200 senior procurement professionals from Merck, Astra Zeneca, Roche, Sanofi, Lonza and other world-leading pharmaceutical businesses over three days. 


We look forward to meeting you there.

May 7, 2026
We are delighted to announce and congratulate Ash Alavijeh on his appointment as Chief Operating Officer at Pharmidex . Ash has been an integral part of Pharmidex’s journey, bringing strong leadership, strategic vision and a deep commitment to advancing our capabilities in drug discovery and development. In his new role as COO, he will play a key part in driving operational excellence and supporting the continued growth of the company. This appointment reflects both Ash’s contributions to date and our confidence in his leadership as we continue to expand and evolve. Please join us in congratulating Ash on this well-deserved achievement.
May 5, 2026
Asthma affects over 260 million people worldwide and remains a significant unmet medical need. At Pharmidex , we are proud to support the development of next-generation respiratory therapies through: In vivo respiratory disease models Whole Body Plethysmography (WBP) for functional readouts Integrated PK/PD and bioanalysis Our focus is simple: generate high-quality data that enables confident decision-making and accelerates progress for patients. Because behind every dataset is a patient waiting to breathe easier.
May 1, 2026
Early-stage innovators based in Scotland have access to a significant opportunity to advance their programs toward ProofOfConcept, with an additional £2.85M fund from the Scottish Government aimed at supporting early development and enabling further investment. 🗓️ Deadline: 8th May At Pharmidex , we work alongside our partners to generate robust, translational data that supports confident decision-making across early discovery and preclinical development. Our capabilities include: TargetExpression ModeOfActionStudies TargetEngagement HitIdentification ADME and PK profiling If you are preparing an application and require scientific input or timely quotations, we would be pleased to support your programme. 🔗 https://lnkd.in/eZ6vVjgN
More Posts